Very very late stent thrombosis: 9.5 years after DES implantation  by Gupta, Sanjiv
i n d i a n h e a r t j o u rn a l 6 8 ( 2 0 1 6 ) s 3 9 – s 4 3
Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.elsevier.com/locate/ihjCase Report
Very very late stent thrombosis: 9.5 years after DES
implantationSanjiv Gupta
Consultant Interventional Cardiologist, SDM Hospital, Jaipur, Indiaa r t i c l e i n f o
Article history:
Received 6 December 2015
Accepted 25 January 2016
Available online 11 February 2016
Keywords:
VLST
VVLST
a b s t r a c t
Very late stent thrombosis (VLST) has been recognized as a class effect of 1st generation drug
eluting stents (DES) implantation. Although rare, VLST has been reported between 1 and
4 years after DES implantation. Very very late stent thrombosis (VVLST) occurringmore than
5 years after DES implantation is extremely rare. We report the ﬁrst case of a VVLST from
India occurring 3465 days (9.5 years) after DES implantation with a brief discussion on its
pathogenesis and prevention.
# 2016 Cardiological Society of India. Published by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Myocardial infarction1. IntroductionPercutaneous coronary intervention (PCI) is the standard of
care for patient with ST elevation myocardial infarction
(STEMI). Drug eluting stents (DES) are preferred over bare
metal stents (BMS) since DES could signiﬁcantly reduce in-
stent restenosis (ISR) by inhibiting neo-intimal proliferation.
However, stent thrombosis (ST) remains a rare but life
threatening complication of all stent deployment. ST usually
presents as sudden death or STEMI with hypotension,
arrhythmias, or acute heart failure. According to Academic
Research Consortium criteria and classiﬁcation, ST can occur
either acutely (within 24 h), subacutely (within 1–30 days), late
(1–12 months) or very late (beyond one year) after stent
implantation.1 Very late stent thrombosis (VLST) occurred
more frequently with 1st generation DES than BMS and
majority of VLST occurred within 1–4 years of stent implanta-
tion.2 VLST is extremely rare after ﬁve years of stent
implantation. The ﬁrst case was reported in 2009.3 A new
term ‘‘very (or extreme) very late stent thrombosis (VVLST)’’E-mail address: gupta98tanya@gmail.com.
http://dx.doi.org/10.1016/j.ihj.2016.01.018
0019-4832/# 2016 Cardiological Society of India. Published by Elsevier
(http://creativecommons.org/licenses/by-nc-nd/4.0/).was suggested when ST occurred after ﬁve years of stent
implantation. The second case of VVLST occurring after ﬁve
years of implantation was reported in 2011.4 In 2014,
Kaliyadan5 published a case series of 7 patients with VVLST
over a period from 2008 to 2013, where the interval between
stent implantation and VVLST varied from 5.6 to 7.1 years.
We report the ﬁrst case of VVLST presenting as STEMI from
India occurring 3465 days (9.5 years) after implantation of 1st
generation DES.
2. Case reportA 55-year-old man ﬁrst reported in December 2005 with acute
substernal chest pain of 36 h duration. He presented with
shock and cardiac arrest. He was revived with active
cardiopulmonary resuscitation. Electrocardiogram revealed
acute inferior wall STEMI with complete heart block. He was a
chronic smoker for over 20 years. There was neither history of
diabetes, hypertension, angina nor any family history of
ischemic heart disease or stroke. He was mildly overweightB.V. This is an open access article under the CC BY-NC-ND license
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) s 3 9 – s 4 3S40with BMI 27 kg/m2. Investigations revealed normal hemato-
logical data, blood sugar (R) 98 mg/dl, serum creatinine 1.0 mg/
dl, normal lipid proﬁle and positive trop T. 2D-ECHO showed
inferior wall hypokinesia with EF 40% and no mitral regurgita-
tion (MR). He received aspirin (325 mg), clopidogrel (600 mg),
and atorvastatin (80 mg) in the intensive coronary care unit.
He underwent emergency temporary pacing (TPI) and coro-
nary angiography which showed normal left main (LM) and
left circumﬂex artery (LCx). The mid left anterior descending
artery (LAD) showed 95% stenosis. The right coronary artery
(RCA) was proximally occluded (100%) with thrombus. He
underwent PCI to the RCA with implantation of two 1st
generation serolimus eluting stents (SES) (3  33 mm  16 atm
and 2.75  38 mm  18 atm) and one SES to LAD (2.75 
28 mm  16 atm). He received GpIIb/IIIa blocker (Eptiﬁbatide)
in the catheterization laboratory in view of large thrombus
burden. His recovery was uneventful and TPI was removed
after 24 h. He was discharged on 4th day on daily aspirin
(150 mg), clopidogrel (75 mg), metoprolol (25 mg) and atorvas-
tatin (80 mg). He has been on regular follow-up every
3–6 months. The clopidogrel was stopped after 12 months,
and he was advised to continue aspirin (150 mg), metoprolol
(50 mg), and atorvastatin (20 mg) daily indeﬁnitely.
The patient remained asymptomatic on the above medica-
tion and was on regular medical follow-up. There was no
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Fig. 1 – TIMI 3 flow revasculardiscontinuation of medical therapy at any time. On May 15,
2015 he presented to the cardiac emergency with chest
heaviness and giddiness for the last 30 min. His pulse rate
was 40/min irregularly irregular and blood pressure 90/
60 mmHgwith few basal crepts. His ECG showed acute inferior
wall STEMIwith slowatrialﬁbrillation (AF, 40 bpm). TropTwas
positive. 2D-ECHO showed LVH with hypokinesia of inferior
wall and no MR. Random blood sugar was 110 mg/dl, HbA1c
6.0, INR 1.4, creatinine 1.2 mg/dl, SGOT 86 U/L, total cholesterol
128 mg/dl, HDL 42 mg/dl, LDL 69 mg/dl and TG 87 mg/dl.
Patient underwent emergency temporary pacing (via right
femoral vein) and coronary angiography (via right radial
approach). His angiography showed occluded proximal RCA1
(100% VVLST), new disease in proximal LCx (90%), and no ISR
on LAD. He was given 60 mg prasugrel in the catheterization
laboratory before PCI. He underwent primary PCI to RCA with
implantation of two 2nd generation everolimus eluting stent
(EES) and one 2nd generation zotarolimus eluting stent (ZES) to
the LCx. TIMI 3 ﬂow was achieved after complete revasculari-
zation of culprit vessels (Fig. 1) without any need for
thrombosuction or glycoprotein IIb/IIIa inhibitors. Patient
returned to sinus rhythm on catheterization table. Temporary
pacingwas removed after 24 h and patient discharged on third
post-operative day on aspirin (150 mg), prasugrel (10 mg),
atorvastatin (80 mg), and carvedilol (20 mg). The current planization of culprit vessels.
i n d i a n h e a r t j o u rn a l 6 8 ( 2 0 1 6 ) s 3 9 – s 4 3 S41for dual antiplatelet therapy (DAPT) is to give aspirin and
prasugrel for one year and thereafter to shift to combination of
aspirin with clopidogrel indeﬁnitely in the absence of any
contraindication.
3. DiscussionToday DES is preferred over BMS due to their property of
reducing ISR. However DES implantation is associated with
delayed arterial healing resulting in delayed endothelializa-
tion, uncovered stent struts, and stent mal-apposition. The
pathological process of neo-atherosclerosis sets in within the
neo-intima. These changes have been identiﬁed as the basic
pathology of VLST in 62 coronary lesions from 46 human
autopsies resulting in VLST due to plaque rupture.6 Neo-
atherosclerosis in the neointima of stent is the ﬁnal pathway
of VLST and stent failure.7
In-stent neoatherosclerosis has emerged as the most
signiﬁcant contributing factor toward the genesis of VLST
occurring after the implantation of DES and may account for
up to 30% of VLST at autopsy.8 Histologically neoathero-
sclerosis is characterized by an accumulation of lipid laden
foamy macrophages with (or without) necrotic core forma-
tion and calciﬁcation within the neointima of the stent.
Neoatherosclerosis may be associated with atherosclerotic
process in the other native arterial vessels.9 Neoathero-
scloerosis in the stent causing VLST may thus present with
accompanying signiﬁcant blockage in other native vessels.
However neoatherosclerosis develops gradually over
months or years after DES implantation, while atheroscle-
rosis in native vessels develops more slowly over decades.8
The mechanism underlying developments of neoathero-
sclerosis is little understood at present. The risk factors for
neoatherosclerosis and the effective preventive strategies
are still to be established. Some of the risk factors could be
functional immaturity of the intimal endothelium, uncov-
ered struts, overlapping stents, malapposition of stents,
plaque rupture, hypersensitivity reactions, and neointimal
erosion. Modern methods to study and evaluate neoathero-
sclerosis during life include serial angioscopy, virtual
histology intravascular imaging and ultrasound (IVUS),
optical coherence tomography (OCT), quantitative angiogra-
phy, near infra-red spectroscopy and other methods of
molecular imaging.8,9 Due to non-availability of OCT
and IVUS at our center, we could not perform these
latest imaging procedures, which would have provided
additional information regarding delayed vascular re-
endothelization, stent malapposition, stent fracture, and
neo-atherosclerosis.
The patient was diagnosed to have VLST and not ISR on
following grounds:(a) The patient was asymptomatic prior to his presentation
with STEMI.(b) ISR usually presents within the ﬁrst few years after stent
implantation. The patients usually have progressive
angina and need uptitration of medical therapy. Our
non-diabetic patient was asymptomatic and stable on
medical therapy since 2005.(c) Clinical proﬁle of present illness with STEMI, hypotension,
and arrhythmia favors an acute event rather than
restenosis.(d) Stress thallium done earlier was not suggestive of any
reversible ischemia thereby lowering the possibility of
restenosis
Propensity of ST is maximal up to 3–4 years after
implantation. However, it remains unknown, whether the
risk of ST eventually abates or persists indeﬁnitely. VVLST is
an extremely rare event.We report the ﬁrst case of VVLST from
India. Chronic smoking and mild raised BMI were the two
obvious risk factors. The patient was neither diabetic nor
hypertensive. The patient had receivedDAPT for one year after
the index procedure and was on aspirin 150 mg daily at the
time of developing ST. The clinical proﬁle has been compared
with other published reports in Table 1.
Following DES implantation, DAPT is normally recom-
mended for a minimum period of one year followed by aspirin
alone indeﬁnitely. ST is, however, a complex multi-factorial
process depending upon many factors including procedural
factors, patient characteristics, and pharmacological inter-
ventions.10 Procedural factors include stent generation type,
stent length, and extent of stent apposition. The lesion factors
include ostial lesions, bifurcation lesions and small vessels.
The patient risk factors are hypercholesterolemia, diabetes,
hypertension, obesity, malignancy and old age. Pharmacolog-
ical factors are the duration of DAPT, the increased rebound
clotting tendencies on cessation of DAPT and slow metabo-
lizers of antiplatelet pro-drugs. Exact duration of recom-
mended DAPT remains a subject of debate.10–12 One standard
DAPT regime may not seem to beneﬁt all patients equally.
Every patient has a unique risk of either bleeding or ST. These
factors play an important role in deciding the duration of DAPT
therapy for the prevention of VLST and VVLST.12 A personal-
ized DAPT regime based on the individual bleeding hazards
and the ischemic risks may be a more logical way in the
future.12
Continuation of DAPT is the preferred method to prevent
the risk of ST in DES implantation. In the recent DAPT trial,
more than 9000 patients with DES implantation were
randomized to receive either 12 months or 30 months of
DAPT.13 The primary end point of cardiac death, myocardial
infarction or stroke was signiﬁcantly decreased with
30 months in comparison with 12 months DAPT (4.3 vs
5.9%, p < 0.001). However the incidence of bleeding also
increased with prolonged DAPT. There may be an increase
in the CV events within 3 months of DAPT withdrawal.10
Whether DAPT cessation unmasks the patients with incom-
plete stent endothelialization or vulnerable plaque or repre-
sents true platelet aggregability remains to be determined.
There may be a small subgroup of patients, who may beneﬁt
from a prolonged or indeﬁnite DAPT but the recognition of
such patients is difﬁcult. Coronary angioscopy, IVUS, and OCT
may be informative.8
There is a growing literature suggesting that newer DES
(2 or 3 generations) are much safer in terms of ST.14 Spanish
ESTROFA-A registry has shown similar results with zotaroli-
mus eluting stents (ZES) and ZES-RESOLUTE. SPIRIT studies
have shown that the incidence of VLST with EES is less than
Table 1 – Comparison of clinical profile of VVLST case reports.
Present case Layland
(Ref. no. 3)
Jennifer (Ref. no. 4) Kaliyadan (Ref. no. 5)
Number of patients 1 1 1 7
Sex Male Male Male Male 6, female 1
Age (years) 65 64 69 30–70 (m = 54)
Time interval between
stent deployment
[5_TD$DIFF]and stent thrombosis
3465 days (9.5 years) 2037 days 2506 days 2010–2610 days (m = 2220 days)
Type of DES SES SES SES SES = 4, PES = 3
Clinical presentation STEMI STEMI STEMI STEMI 6
NSTEMI 1
Risk factors Overweight
Chronic smoker
– Hypertension
Hypercholesterolemia
Chronic smoker
Stoppage of clopidogrel
10 days prior to onset
of ST
Hypertension (n = 4)
Diabetes (n = 1)
Hypercholesterolemia (n = 7)
Chronic smoking (n = 6)
Obesity (n = 6)
Stoppage of DAPT 7–14 days
prior to ST (n = 3)
Type of stent deployed
to treat ST
2nd generation DES EES – BMS BMS
VVLST – very very late stent thrombosis; m –mean; DES – drug eluting stent, SES – serolimus eluting stent; PES – paclitaxel eluting stent; STEMI
– ST elevation myocardial infarction; NSTEMI – nonST elevation myocardial infarction; ST – stent thrombosis; DAPT – dual antiplatelet therapy;
BMS – bare metal stent; EES – everolimus eluting stent; n = number of patients
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analysis of 8 studies of biodegradable polymer III generation
stents has shown a still lower incidence of VLST.16 We
hopefully expect that newer stents will reduce or eliminate
the problem of ST.
In India, cost and reimbursement policies still permit
patients to receive 1st generation DES. This and earlier case
reports clearly highlight the risk of VVLST with the 1st
generation DES. It may be advisable that these, small but
not insigniﬁcant, number of patients be monitored for ST and
in absence of any contraindication, be continued indeﬁnitely
on DAPT.
Bioresorbable vascular scaffold may be the ﬁnal answer to
avoid VLST or VVLST. However its use is limited at this time,
because the device is bulky and expensive, not available in all
sizes and needs aggressive preparation of vascular bed before
implantation.
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